1
|
Tavazzi S, Cacciatori C, Comero S, Fatta-Kassinos D, Karaolia P, Iakovides IC, Loutsiou P, Gutierrez-Aguirre I, Lengar Z, Bajde I, Tenson T, Kisand V, Laas P, Panksep K, Tammert H, Mariani G, Skejo H, Gawlik BM. Short-term stability of wastewater samples for storage and shipment in the context of the EU Sewage Sentinel System for SARS-CoV-2. J Environ Chem Eng 2023; 11:109623. [PMID: 36890876 PMCID: PMC9979635 DOI: 10.1016/j.jece.2023.109623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 02/06/2023] [Accepted: 03/01/2023] [Indexed: 06/18/2023]
Abstract
In the context of an EU-wide surveillance system for SARS-CoV-2 in wastewater, recommended by the European Commission, this study aims to provide scientific support to the adequacy of transport and storage conditions of samples both in terms of duration and samples temperature. Three laboratories in Slovenia, Cyprus and Estonia investigated the short-term, one-week, isochronous stability of wastewater samples by RT-qPCR based detection of SARS-CoV-2 genes. The results were tested for statistical significance to determine uncertainty of quantification and shelf-life, at testing temperatures of + 20 °C and - 20 °C, relative to reference at + 4 °C. Samples were collected from three urban wastewater treatment plant influents and analysed respectively for SARS-CoV-2 genes N1, N2 (Laboratory 1), N2, E (Laboratory 2) and N3 (Laboratory 3), with various analytical methods. For a period of 7/8 days at + 20 °C, decreasing trends of measured concentrations were observed for all genes resulting in instability according to the statistical analysis, while at - 20 °C the trend of variation was stable only for N1, N2 (Laboratory 1) and N3 (Laboratory 3). Trends for gene E concentrations at - 20 °C (Laboratory 2) could not be tested statistically for stability because of lack of data. Over a period of just 3 days at + 20 °C, the variation was statistically non-significant indicating stability for genes N1, E and N3 for laboratories 1, 2 and 3, respectively. Nonetheless, the outcome of the study presents evidence to support the choice of the selected temperature at which samples shall be preserved during storage before analysis or transport to the laboratory. The conditions (+4 °C, ∼ few days) chosen for EU wastewater surveillance are in accordance with these results, highlighting the importance of stability testing of environmental samples to determine the short-term analytical uncertainty.
Collapse
Affiliation(s)
- S Tavazzi
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| | - C Cacciatori
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| | - S Comero
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| | - D Fatta-Kassinos
- Nireas-International Water Research Centre, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
- Department of Civil and Environmental Engineering, School of Engineering, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
| | - P Karaolia
- Nireas-International Water Research Centre, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
| | - I C Iakovides
- Nireas-International Water Research Centre, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
- Department of Civil and Environmental Engineering, School of Engineering, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
| | - P Loutsiou
- Nireas-International Water Research Centre, University of Cyprus, P.O. Box 20537, 1678 Nicosia, Cyprus
| | | | - Z Lengar
- National Institute of Biology, Vecna Pot 111, SI-1000 Ljubljana, Slovenia
| | - I Bajde
- National Institute of Biology, Vecna Pot 111, SI-1000 Ljubljana, Slovenia
| | - T Tenson
- Institute of Technology, University of Tartu, Nooruse 1, E-50411 Tartu, Estonia
| | - V Kisand
- Institute of Technology, University of Tartu, Nooruse 1, E-50411 Tartu, Estonia
| | - P Laas
- Institute of Technology, University of Tartu, Nooruse 1, E-50411 Tartu, Estonia
| | - K Panksep
- Institute of Technology, University of Tartu, Nooruse 1, E-50411 Tartu, Estonia
| | - H Tammert
- Institute of Technology, University of Tartu, Nooruse 1, E-50411 Tartu, Estonia
| | - G Mariani
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| | - H Skejo
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| | - B M Gawlik
- Ocean and Water Unit, Joint Research Centre, European Commission, via E. Fermi 2749, T.P. 120, I-21027 Ispra, Italy
| |
Collapse
|
2
|
Cozzolino M, Mossetti L, Mariani G, Pellicer A, Garrido N. P-694 Dosage of exogenous gonadotropins is not related to blastocyst aneuploidy or cumulative live-birth rates in PGT-A cycles. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Does dosage of gonadotropins affect aneuploidy rate rates or cumulative live birth rates (CLBRs) after the transfer of euploid embryos?
Summary answer
We did not find evidence that dosage gonadotropin influenced significantly the rate of aneuploidy and CLBRs after transfer of euploid embryos.
What is known already
Aneuploidy rates increase steadily with age, reaching >80% in women >42 years old. The goal of controlled ovarian stimulation obtaining more embryos to biopsy through the recruitment of several follicles, reaching more euploid embryos. However, several studies have suggested that a high response to stimulation might be embryotoxic and/or increase aneuploidy rates by enhancing the abnormal segregation of chromosomes during meiosis. Furthermore, a study on young donors showed differences in the euploidy rates, suggesting an iatrogenic etiology resulting from different stimulation methods.
Study design, size, duration
A multicenter retrospective study, with the preimplantation genetic test for aneuploidy (PGT-A) between January 2013 and January 2020 collected from clinics IVIRMA in Europe. 6832 cycles of in vitro fertilization (IVF) with PGT-A were included in the study
Participants/materials, setting, methods
A total of 62131 embryos were analyzed for ploidy status. Embryos that were subjected to chromosomal analysis were performed blastomere by aCGH (array Comparative Genomic Hybridization) or NGS (Next-Generation Sequencing) analysis. The embryos were biopsied on days 5 and 6. Women were divided into two age groups (<37 and ≥37 years old). Outcomes were compared between different total gonadotropin dosages (<3000 and ≥3000 IU), the dosage of hMG, and numbers of oocytes retrieved.
Main results and the role of chance
The total number of aneuploid embryos was 28336 of the 62131 embryos genetically screened using PGT-A. The embryonic aneuploidy rate was 59.4% (95%CI 58.5-60.3). In the group of women with gonadotropins dosage <3000 IU the embryonic aneuploidy rate was 59.7% (95%CI 58.7-60.8) and in the group with gonadotropins dosage ≥3000 IU was 58.7% (95%CI 57.1-60.3) with no significant difference between them (P = 0.279). In the group of younger patients (<37 y.o) the aneuploidy rate demonstrated no significant differences between patients who received low gonadotropin dosages and patients with high gonadotropin dosages (P = 0.06). Aneuploidy rates in the group of older patients (≥37 y.o) were similar regardless of gonadotropin dosing (P = 0.21). Dividing the according to the number of oocytes retrieved (10, 11-15, >15), the analysis of aneuploidy rate revealed no association between the gonadotropin dosages administrated depending on the total number of retrieved oocytes and age. The aneuploidy rate was also analyzed considering the administration of hMG, there was no statistical difference in the aneuploidy rate with low or high hMG dosages also when it was stratified by age. The cumulative live-birth rate in the groups of different gonadotropins dosage and different ages of patients was similar across the group.
Limitations, reasons for caution
The retrospective nature is the major limitation of this study, also patients included in the study received PGT-A using NGS and CGH arrays technology. The aCGH analysis used is less sensitive than more recent NGS technology.
Wider implications of the findings
Our study demonstrated that gonadotropin dosage did not affect aneuploidy rate or cumulative live-birth rates suggesting that the high doses of gonadotropins used in ART cycles may be safe.
Trial registration number
not applicable
Collapse
Affiliation(s)
| | | | | | | | - N Garrido
- Fundacion IVI-IIS la Fe , Valencia, Valencia, Spain
| |
Collapse
|
3
|
Forte M, Zimbardi V, Mariani G, Pellicer A, Garrido N, Galliano D. P-507 Psychosocial and motivational drivers of the increased IVF engagement of infertile couples following Covid-19. Hum Reprod 2022. [PMCID: PMC9384349 DOI: 10.1093/humrep/deac107.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
What are the main psychosocial motivational factors behind the increased IVF adoption during the Covid-19 Pandemic?
Summary answer
During the Covid -19 Pandemic more time invested in marital relationships prompted infertile couples to act and engage in IVF treatments.
What is known already
The Covid 19 Pandemic has generated a sense of lack of control and fear for the future in many individuals. However, like several life-threatening events, it could also have positive effects, motivating people to take significant actions for their life course. Little has been reported on the consequences that the Pandemic has generated on the infertile couple’s attitude toward reproduction, IVF treatments engagement and childbearing desire. We aimed to address if during the Pandemic, there was an increase of IVF demand and what motivational factors prompted infertile patients to pursue IVF as compared to the pre-pandemic.
Study design, size, duration
This is a prospective multicenter observational control-case study assessing the relational, emotional, and environmental motivational factors driving infertile couples to purse their first IVF treatment during the Covid-19 Pandemic in different IVF clinics as Valencia, Madrid, Rome, and Chile. To assess the growth rate in IVF activity at recruiting sites, number of cycles was compared over a 18 months period between the pre-pandemic and pandemic. The survey was run between September 2021 to January 2022.
Participants/materials, setting, methods
An ad hoc survey was developed to explore the main relationship, emotional and socioeconomical factors responsible for the IVF engagement. The electronic survey was delivered to 13585 patients attending the recruiting clinics from December 2018 to March 2020 for Prepandemic and from March 2020 to December 2021 for the Pandemic ones, and they were asked to rate their agreement for each answer on a five-points Likert scale.
Main results and the role of chance
For most clinics, data derived from national patients only showed a significant IVF demand increase (5.5-8.7%) for all indicators (number of started ovarian stimulations, oocyte pickups, and embryo transfers). Of 13685 patients receiving the survey only 1556 (810 prepandemic, 746 pandemic, response rate: 11%) completed it. Demographic and infertility history data (including male/female, infertility length, previous children and miscarriages, ethnicity) were homogeneous between two groups. However, the infertility length and the proportion of donation cycles were slightly lower in the pandemic group (2.3 vs 2.1) years and 24.1% vs 19% for pre-pandemic and pandemic, respectively; p < 0.001). Only 25.34% (95%CI: 22.2-28.6) of Pandemic patients experienced their referral clinic closing, and 19.17% (95% CI: 16.4-22.1) public hospital closing, and 30.56% (95%CI:27.2-34.01) valued the use of telemedicine in the IVF positively. Interestingly, over 90.21% (95%CI:87.8-92.2) of pandemic patients started childbearing desire before the Pandemic, and about 68.63% (95%CI:65.1-71.9) knew already about their infertility. This suggests the Pandemic had represented a strong trigger for infertile patients to reframe their reproductive intention. Among all the motivational factors addressed in the survey, the increased time to invest in marital relationship was the stronger driver for pursuing IVF for Pandemic patients (OR:1.48; 95%CI: 1.16-1.89; p < 0.01).
Limitations, reasons for caution
Not all potential drivers for IVF attainment have been included in the survey and unexplored factors might have played a role. Other reasons for caution include the possibility of response bias. However, the prospective design and the large multicentre/international setting of the study helped mitigating the effect of specific/local confounding.
Wider implications of the findings
The knowledge gathered here will be crucial to design more effective strategies to cope with patients’ needs during the pandemic. Furthermore, this study can provide a valuable resource for understanding psychosocial factors responsible of the ongoing decline in the natality rate in many developed countries, such as disincentivizing couples’ relationships.
Trial registration number
not applicable
Collapse
Affiliation(s)
- M Forte
- IVI Foundacion, Fertility Research Centers , Valencia, Italy
| | - V Zimbardi
- IVI-RMA Rome, Reproductive Medicine , Rome, Italy
| | - G Mariani
- IVI-RMA Rome, Reproductive Medicine , Rome, Italy
| | - A Pellicer
- IVI-RMA Rome, Reproductive Medicine , Rome, Italy
| | - N Garrido
- IVI Foundacion, Fertility Research Centers , Valencia, Italy
| | - D Galliano
- IVI-RMA Rome, Reproductive Medicine , Rome, Italy
| |
Collapse
|
4
|
Vanreusel V, Galante F, Gasparini A, Leblans P, Mariani G, Pacitti M, Vandenbroucke D, Felici G, de Freitas Nascimento L, Verellen D. MO-0050 Optically stimulated luminescence dosimetry as alternative for radiochromic film in UHDR e-beams? Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02283-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. Ann Oncol 2022; 33:534-543. [PMID: 35182721 DOI: 10.1016/j.annonc.2022.02.004] [Citation(s) in RCA: 112] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 02/08/2022] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND High-risk triple negative breast cancers (TNBC) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy, thus representing an area in need of new therapeutic approaches. PD-L1 expression is an adaptive mechanism of tumour resistance to tumour infiltrating lymphocytes, which in turn are needed for response to chemotherapy. Overall, available data support the concept that blockade of PD-L1/PD-1 check-point may improve efficacy of classical chemotherapy. PATIENTS AND METHODS Two-hundred-eighty patients with TNBC were enrolled in this multicentre study (NCT002620280) and randomized to neoadjuvant carboplatin AUC 2 and nab-paclitaxel 125 mg/m2 iv on days 1 and 8, without (N = 142) or with (N = 138) atezolizumab 1200 mg iv on day 1. Both regimens were given q3 weeks for 8 cycles before surgery and 4 cycles of an adjuvant anthracycline regimen. The primary aim of the study is to compare event-free survival, an important secondary aim was the rate of pathological complete remission (pCR defined as absence of invasive cells in breast and lymph nodes). The primary population for all efficacy endpoints is the intention-to-treat population. RESULTS The intention-to-treat analysis revealed that pCR rate after treatment with atezolizumab (48.6%) did not reach statistical significance compared to no atezolizumab [44.4%: odds ratio (OR) 1.18; 95% CI 0.74-1.89; P = 0.48]. Treatment-related adverse events were similar with either regimen except for a significantly higher overall incidence of serious adverse events and liver transaminases abnormalities with atezolizumab. CONCLUSIONS The addition of atezolizumab to nab-paclitaxel and carboplatin did not significantly increase the rate of pCR in women with TNBC. In multivariate analysis the presence of PD-L1 expression was the most significant factor influencing rate of pCR (OR 2.08). Continuing follow up for the event-free survival is ongoing, and molecular studies are under way.
Collapse
Affiliation(s)
- L Gianni
- Fondazione Michelangelo, Milano, Italy.
| | - C S Huang
- National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan
| | - D Egle
- Department of Gynecology, Brust Gesundheit Zentrum Tirol, Medical University Innsbruck, Austria
| | - B Bermejo
- Hospital Clinico Universitario, Valencia, Spain
| | - C Zamagni
- Addarii Medical Oncology IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy
| | - M Thill
- Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
| | - A Anton
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | - S Russo
- Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - E M Ciruelos
- Hospital Universitario 12 de octubre, Madrid, Spain
| | - R Greil
- 3rd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; and Cancer cluster Salzburg, Austria
| | - V Semiglazov
- NN Petrov Research Inst of Oncology, St. Petersburg, Russia
| | - M Colleoni
- IEO, Istituto Europeo di Oncologia, IRCCS, Milano, Italy
| | - C Kelly
- Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland
| | - G Mariani
- Istituto Nazionale Tumori, Milano, Italy
| | - L Del Mastro
- IRCCS Ospedale Policlinico San Martino, UO Breast Unit, Genova, Università di Genova, Dipartimento di Medicina Interna e Specialità Mediche (Di.M.I.), Genova - Italy
| | - I Maffeis
- Fondazione Michelangelo, Milano, Italy
| | | | - G Viale
- IEO, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; University of Milan, Milano, Italy
| |
Collapse
|
6
|
Cappare P, Ferrini F, Mariani G, Nagni M, Cattoni F. Implant rehabilitation of edentulous jaws with predominantly monolithic zirconia compared to metal-acrylic prostheses: a 2-year retrospective clinical study. J BIOL REG HOMEOS AG 2021; 35:99-112. [PMID: 34425665 DOI: 10.23812/21-4supp1-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Limited data are available on the clinical outcomes of patients with edentulism treated with predominantly monolithic zirconia fixed complete dentures (FCDs) compared to traditional restoration materials. The purpose of this study was to analyze the differences in terms of complications and failures of definitive full-arch implant rehabilitations made in metal-acrylic versus those made in monolithic zirconia with porcelain veneering limited to non-functional areas. This retrospective clinical study included 50 patients treated between January 2015 and December 2018, with 222 implants inserted in fifty edentulous jaws. All patients were treated with immediately loaded full-arch fixed prostheses (22 maxillary; 28 mandibular) each supported by four to six implants (two/four axial, two distally tilted). All 25 zirconia prostheses were predominantly monolithic with ceramic veneering limited to non-functional areas. The primary outcome measures were prosthetic success of the definitive restoration and implant survival. The secondary outcome measures were full mouth plaque score, full mouth bleeding score, peri-implant probing depths and periimplant keratinized tissue. All implants and prostheses analyzed had a minimum of 2 years of followup. No chipping of the veneered facial porcelain or other technical complication was observed over the study period achieving a prosthesis survival and success rate of 100%. No implants were lost, achieving a 100% survival rate. Bleeding on probing was positive in 33% and 13% of probing sites for metal-acrylic prosthesis and zirconia prosthesis, respectively (p = 0.0445). Plaque index was positive in 76% and 53% of probing sites for metal-acrylic prosthesis and zirconia prosthesis, respectively (p = 0.0491). Mean probing depth was 1.74mm (SD 0.89mm) for the 106 implants supporting metal-acrylic prosthesis and 1.52mm (SD 0.63mm) for the 116 implants supporting zirconia prosthesis (p=0.0412). No other statistically significant differences were found between the two groups. The results of this retrospective evaluation showed that predominantly monolithic zirconia is a feasible alternative to the conventional metal framework acrylic for full arch implant-supported prosthesis. The restauration material did not influence the failure rate and complication risk of both prosthesis and implants.
Collapse
Affiliation(s)
- P Cappare
- Dental School, Vita-Salute University and Department of Dentistry, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Ferrini
- Dental School, Vita-Salute University and Department of Dentistry, IRCCS San Raffaele Hospital, Milan, Italy
| | - G Mariani
- Dental School, Vita-Salute University and Department of Dentistry, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Nagni
- Dental School, Vita-Salute University and Department of Dentistry, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Cattoni
- Dental School, Vita-Salute University and Department of Dentistry, IRCCS San Raffaele Hospital, Milan, Italy
| |
Collapse
|
7
|
Tapia JL, Toso A, Vaz Ferreira C, Fabres J, Musante G, Mariani G, Herrera TI, D'Apremont I. The unfinished work of neonatal very low birthweight infants quality improvement: Improving outcomes at a continental level in South America. Semin Fetal Neonatal Med 2021; 26:101193. [PMID: 33478876 DOI: 10.1016/j.siny.2021.101193] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Neonatal mortality rate varies between 4.2 and 18.6 per thousand by country in South America. There is little information regarding the outcomes of very low birth weight infants in the region and mortality rates are extremely variable ranging from 6% to over 50%. This group may represent up to 50-70% of the neonatal mortality and approximately 25-30% of infant mortality. Some initiatives, like the NEOCOSUR Network, have systematically collected and analyzed epidemiological information on VLBW infants' outcomes in the region. Over a 16-year period, survival without major morbidity improved from 37 to 44%. However, mortality has remained almost unchanged at approximately 27%, despite an increase in the implementation of the best available evidence in perinatal practices over time. Implementing quality improvement initiatives in the continent is particularly challenging but represents a great opportunity considering that there is a wide margin for progress in both care and outcomes.
Collapse
Affiliation(s)
- J L Tapia
- Department of Neonatology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - A Toso
- Department of Neonatology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - C Vaz Ferreira
- Department of Neonatology, Centro Hospitalario Pereira Rossell, Universidad de La República, Montevideo, Uruguay.
| | - J Fabres
- Department of Neonatology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - G Musante
- Department of Maternal and Child Health, Hospital Universitario Austral, Pilar, Argentina.
| | - G Mariani
- Department of Pediatrics, Division of Neonatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
| | - T I Herrera
- Department of Neonatology, Centro Hospitalario Pereira Rossell, Universidad de La República, Montevideo, Uruguay.
| | - I D'Apremont
- Department of Neonatology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| |
Collapse
|
8
|
Bianchini G, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos E, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Smart C, Valagussa P, Viale G, Gianni L. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2241] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Guarneri V, Cinieri S, Orlando L, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Salvo G, Conte P. Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz118.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, Mariani G, Trifirò G. PETC/CT with 18F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J Endocrinol Invest 2019; 42:419-426. [PMID: 30094743 DOI: 10.1007/s40618-018-0931-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 07/27/2018] [Indexed: 11/25/2022]
Abstract
PURPOSE Identification of pathologic parathyroid glands in primary hyperparathyroidism, traditionally based on neck ultrasound (US) and/or 99mTc-Sestamibi scintigraphy, can be challenging. PET/CT with 18F-Fluorocholine (18F-FCH) might improve the detection of pathologic parathyroid glands. We aimed at comparing the diagnostic performance of 18F-FCH-PET/CT with that of dual-phase dual-isotope parathyroid scintigraphy and neck US. METHODS Thirty-four consecutive patients with primary hyperparathyroidism were prospectively enrolled, 7 had normocalcemic hyperparathyroidism, and 27 had classic hypercalcemic hyperparathyroidism. All patients underwent high-resolution neck US, dual-phase dual-isotope 99mTc-Pertechnetate/99mTc-Sestamibi scintigraphy, and 18F-FCH-PET/CT. RESULTS In the whole patients' group, the detection rates of the abnormal parathyroid gland were 68% for neck US, 71% for 18F-FCH-PET/CT, and only 15% for 99mTc-Sestamibi scintigraphy. The corresponding figures in normocalcemic and hypercalcemic hyperparathyroidism were 57 and 70% for neck US, 70 and 71% for 18F-FCH-PET/CT, and 0 and 18% for 99mTc-Sestamibi scintigraphy, respectively. In the 17 patients in whom the abnormal parathyroid gland was identified, either at surgery or at fine needle aspiration cytology/biochemistry, the correct detection rate was 82% for neck US, 89% for 18F-FCH-PET/CT, and only 17% for 99mTc-Sestamibi scintigraphy. CONCLUSIONS 18F-FCH-PET/CT can be considered a first-line imaging technique for the identification of pathologic parathyroid glands in patients with normocalcemic and hypercalcemic hyperparathyroidism, even when the parathyroid volume is small.
Collapse
Affiliation(s)
- I Bossert
- Unit of Nuclear Medicine, ICS Maugeri, 27100, Pavia, Italy
| | - S Chytiris
- Unit of Internal Medicine and Endocrinology, ICS Maugeri I.R.C.C.S, University of Pavia, Via S. Maugeri 10, 27100, Pavia, Italy
| | - M Hodolic
- Nuclear Medicine Research Department, Iason, Graz, Austria
- Nuclear Medicine Department, Iason, Graz, Austria
- Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- Nuclear Medicine Department, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy
| | - L Croce
- Unit of Internal Medicine and Endocrinology, ICS Maugeri I.R.C.C.S, University of Pavia, Via S. Maugeri 10, 27100, Pavia, Italy
| | - L Mansi
- Inter-Universitary Research Center for Sustainable Development (CIRPS), Naples, Italy
| | - L Chiovato
- Unit of Internal Medicine and Endocrinology, ICS Maugeri I.R.C.C.S, University of Pavia, Via S. Maugeri 10, 27100, Pavia, Italy.
| | - G Mariani
- Regional Center of Nuclear Medicine, University of Pisa, Pisa, Italy
| | - G Trifirò
- Unit of Nuclear Medicine, ICS Maugeri, 27100, Pavia, Italy
| |
Collapse
|
11
|
Figar Gutiérrez A, Adrover A, Deluca D, Alvarez Calzaretta L, Garcia Fornari G, Portillo S, Konsol CO, Mariani G, Aiello H, Meller C, Izbizky G, Otaño L. Peri-operative considerations for in utero repair of myelomeningocele. Int J Obstet Anesth 2018; 37:135-136. [PMID: 30514591 DOI: 10.1016/j.ijoa.2018.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 10/12/2018] [Accepted: 10/15/2018] [Indexed: 11/29/2022]
Affiliation(s)
- A Figar Gutiérrez
- Servicio de Anestesiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
| | - A Adrover
- Servicio de Anestesiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - D Deluca
- Servicio de Anestesiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - L Alvarez Calzaretta
- Servicio de Anestesiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - G Garcia Fornari
- Servicio de Anestesiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - S Portillo
- Servicio de Neurocirugía Infantil, Hospital Italiano de Buenos Aires, Argentina
| | - C O Konsol
- Servicio de Neurocirugía Infantil, Hospital Italiano de Buenos Aires, Argentina
| | - G Mariani
- Servicio de Neonatología, Hospital Italiano de Buenos Aires, Argentina
| | - H Aiello
- Servicio de Obstetricia, Hospital Italiano de Buenos Aires, Argentina
| | - C Meller
- Servicio de Obstetricia, Hospital Italiano de Buenos Aires, Argentina
| | - G Izbizky
- Servicio de Obstetricia, Hospital Italiano de Buenos Aires, Argentina
| | - L Otaño
- Servicio de Obstetricia, Hospital Italiano de Buenos Aires, Argentina
| |
Collapse
|
12
|
De Sio L, Mariani G, Muzzucconi MG, Chistolini A, Tirindelli MC, Mandelli F. Comparison Between Subcutaneous and Intravenous DDAVP in Mild and Moderate Hemophilia A. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657745] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummarySixteen patients with mild and moderate hemophilia were given Desmopressin (DDAVP) subcutaneously in the absence of any actual bleeding. The response to the drug – in terms of factor VIII coagulant activity rise – became apparent 15 min after the injection, reaching the maximal response after one hour (x̄ 3.2 times the baseline levels; SD 1.21). This response was not different from that elicited using the intravenous route in 18 hemophiliacs of comparable severity after the same time interval. No local or general side-effects were recorded after the subcutaneous administration of DDAVP. We therefore conclude that the subcutaneous route adds further evidence to the reliability of this alternative treatment in mild factor VIII deficiencies, thus making home treatment with this vasopressin analogue possible.
Collapse
Affiliation(s)
- L De Sio
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| | - G Mariani
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| | - M G Muzzucconi
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| | - A Chistolini
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| | - M C Tirindelli
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| | - F Mandelli
- The Department of Human Biopathology, Section of Hematology, University of Rome, “La Sapienza”, Rome, Italy
| |
Collapse
|
13
|
Abstract
SummaryTwenty three patients belonging to 18 different pedigrees of Haemophilia B were studied with regard to ox-brain prothrombin time and its correlation to factor VII.Eleven among them were B-negative (no detectable factor IX antigen), five were B-reduced (factor IX antigen detectable but below the normal values) and seven were B-positive (normal levels of factor IX antigen).Ox-brain prothrombin time was found prolonged (≥ x̄ + 2.5 SD:99% confidence limits) in nine patients. Factor VII Activity (VII: C) was found reduced in 1/11 B-negative, in 2/5 B-reduced and in 4/7 B-positive patients. Factor VII Antigen (VII: Ag) was found normal in all but one patient.The ratio VII:C/VII:Ag was abnormal in eight patients independently from the variant of Haemophilia B. The underlying defect which causes the prolongation of Ox-brain prothrombin time due to factor VII: C mild deficiency is heterogeneous. Age, a mild Vitamin K deficiency, the presence of an inhibitor of Factor VII activation and other unknown causes, may be responsible for this pattern.
Collapse
Affiliation(s)
- M G Mazzucconi
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| | - R M Bertina
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| | - D Romoli
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| | - M Orlando
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| | - G Avvisati
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| | - G Mariani
- The Institute of Haematology, University of Rome, Italy; Haemostasis and Thrombosis Research Unit, Academisch Ziekenhuis, Leiden, Holland; Istituto Superiore di Sanità, Roma, Italy
| |
Collapse
|
14
|
Abstract
SummaryA new factor VII concentrate, made from ACD plasma by a process involving successive absorptions of cryoprecipitate supernatant on DEAE Sephadex and of the resulting supernatant on Al(OH)3, was administered to 10 patients with severe factor VII deficiency. 5 patients received only one dose for treatment of a single bleeding episode, the remaining 5 were given multiple infusions (47) for spontaneous hemorrhages or for the prevention of surgical bleeding. In vivo factor VII recovery ranged from 43 to 126% (average 88%) of the assayed in vitro activity of the concentrate. A dose of 0.5 u/kg was found to produce a 1% rise of the plasma factor VII levels. The mean half-life on injected factor VII as assessed in 7 kinetic studies was 205 min (range 168-234). Spontaneous bleeding was easily controlled by the concentrate and major surgical procedures (two tonsillectomies) could be performed without complications. 1 patient developed HBsAg positive hepatitis, but otherwise no serious side effects were observed. Factor VII concentrate reduces the risk of precipitating circulatory overload associated with the use of plasma and avoids the unnecessary rise of factor II, IX and X which follows prothrombin complex concentrates.
Collapse
Affiliation(s)
- G Mariani
- The Department of Hematology, University of Rome, Italy
| | - P M Mannucci
- The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
| | | | - A Capitanio
- The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
| |
Collapse
|
15
|
Abstract
Summary40 Hemophilia Centers from the USA, Canada, Europe and Japan referred to the International Registry 204 patients with haemophilia A, treated by Immune Tolerance (IT) Protocols over the past two decades because of the presence of an inhibitor to FVIII. 82% of the patients were high responders, while IT was started with low levels of inhibitor (<10 BU) in most (57.3%) of the cases. 69 patients (33.8%) were given the highest FVIII dosage (≥200 IU/kg/day), 71 (34.8%) intermediate dosages (50 - <200) and 64 (31.4%) the lowest dosages (<50). Of 158 patients persevering with treatment long enough to judge the outcome thereof, 107 (67.7%) achieved tolerance, 12 (7,6%) had a partial response, while 39 (24.7%) did not respond. Multivariate logistic regression analysis showed that two variables were independently associated with the highest probability of success: the use of high dose protocols (≥100 IU/kg/day) (p <.0001) and the presence of low levels of inhibitor (<10 BU) at enrollment (p = .004). The Kaplan-Meier inhibitor-free survival curve showed that tolerance is longlasting: only 1 out of 107 patients relapsed and the longest documented tolerant patient has been inhibitor-free for 16 years. 129 hemophiliacs were HIV Ab-negative at enrollment; of the 118 HIV-screened after the treatment, 18 (13.9%) were found to be HIV Ab-positive. IT can indeed modify the natural history of inhibitors to FVIII in hemophilia.
Collapse
Affiliation(s)
- G Mariani
- The Hematology, Department of Human Biopathology, University of Rome, Italy
| | - A Ghirardini
- National AIDS Operational Centre, Istituto Superiore di Sanità, Rome, Italy
| | - R Bellocco
- National AIDS Operational Centre, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
16
|
Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of New Polymorphic Markers in the Factor V Gene: Association with Factor V Levels in Plasma. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650219] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThree novel polymorphisms were found in the repeated region of the large exon 13 of factor V gene, one giving rise to a codon dimorphism (Serl240) and two causing aminoacid substitutions (Hisl299Arg, Leul257Ile). An increasing frequency of the Argl299 (R2 allele) correlated with a decreasing mean plasma factor V activity in the groups of subjects under study, which included 26 unrelated subjects with partial factor V deficiency. Family studies supported the co-inheritance both of low factor V activity and of R2 allele. The reduction of factor V activity associated with the R2 allele was not clinically symptomatic even in the homozygous condition and was characterized by a parallel reduction of antigen in plasma, in which abnormal molecules were not detected. Data suggest that the R2 allele represents a marker in linkage with an unknown defect rather than a functional polymorphism.These studies provide the first evidence of a genetic component in determining factor V levels in plasma and of a genetic linkage between the factor V gene and factor V deficiency. They also define specific haplotypes which are associated with factor V deficiency or with APC resistance (Arg506Gln) and are valuable fools for the study of factor V defects.
Collapse
Affiliation(s)
- B Lunghi
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - L Iacoviello
- The “Angela Valenti” Lab. Thrombosis Pharmacology, 1st. di Ricerche Farmacologiche Mario Negri; Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - D Gemmati
- The Centro Emostasi e Trombosi, Università di Ferrara, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - M G Dilasio
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - E Castoldi
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - M Pinotti
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - G Castaman
- The Divisione di Ematologia - CRS Malattie Emorragiche e Trombotiche, Osp. S. Bortolo, Vicenza, Italy
| | - R Redaelli
- The Div. di Ematologia, Osp. Niguarda, Milano, Italy
| | - G Mariani
- The Dip. di Biopatologia Umana, Sezione di Ematologia, Università La Sapienza, Roma; Italy
| | - G Marchetti
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | - F Bernardi
- The Dip. di Biochimica e Biologia Molecolare, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| |
Collapse
|
17
|
Sorice M, Arcieri P, Griggi T, Circella A, Misasi R, Lenti L, Di Nucci GD, Mariani G. Inhibition of Protein S by Autoantibodies in Patients with Acquired Protein S Deficiency. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650320] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study was undertaken to analyze antibodies to protein S (PS) in patients with an acquired PS deficiency. Plasma from symptomatic patients with acquired (n = 14) or congenital (n = 10) PS deficiency and 10 healthy donors was screened for PS antibodies by immunoblotting and for anti-phospholipid antibodies. PS antibodies (IgG) were detected in five of the patients with acquired PS deficiency. These antibodies belonged to the G1 and G4 immunoglobulin subclasses. IgG fractions from the same 5 patients were shown to inhibit PS activity. The inhibition of PS activity by the 5 IgG fractions was shown to be time-and dose-dependent and was abolished following incubation with purified PS, while no effect was found after absorption with cardiolipin micelles. In addition, anticardiolipin monoclonal or human purified antibodies, failed to exert significant PS inhibition. These findings demonstrate that anti-PS antibodies are able to inhibit PS activity and that this is independent of anti-phospholipid antibodies. Given the clinical features of the patients, these antibodies should be regarded as an expression of the broad autoimmune syndrome involving the phospholipid-binding plasma proteins.
Collapse
Affiliation(s)
- M Sorice
- The Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma “La Sapienza”, Rome
| | - P Arcieri
- Centro Trombosi, Dipartimento di Biopatologia Umana, Università degli Studi di Roma “La Sapienza”, Rome
| | - T Griggi
- The Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma “La Sapienza”, Rome
| | - A Circella
- The Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma “La Sapienza”, Rome
| | - R Misasi
- The Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma “La Sapienza”, Rome
| | - L Lenti
- The Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma “La Sapienza”, Rome
| | - G D Di Nucci
- Centro Trombosi, Dipartimento di Biopatologia Umana, Università degli Studi di Roma “La Sapienza”, Rome
| | - G Mariani
- Cattedra di Ematologia, Universita degli Studi di Palermo, Italy
| |
Collapse
|
18
|
Mariani G, Solinas S, Pasqualetti D, Ghirardini A, Verani P, Buttó S, Lopez M, Moretti T. Induction of Immunotolerance in Hemophilia for High Titre Inhibitor Eradication: A Long-Term Follow-Up. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1651013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThree hemophiliacs with high titre inhibitor were treated with a medium-high FVIII dose schedule (100 IU/kg bw daily) with the aim of inducing the immunotolerance. These patients were followed-up extensively concerning their immunological status and HIV serology. In all of them the inhibitor disappeared and normal FVIII kinetics were obtained after 22, 15 and 29 months. After eradication of the inhibitor, no recurrence took place in any of the patients. All the patients were HIV Ab positive before the beginning of the treatment. In one of them CD4+ cells fell progessively 32 months after the treatment was started, a fullblown AIDS showed up, and the patient died 5½ years after the beginning of the treatment. In the second and third patient the CD4+ cells varied widely but remained >400/μl during the whole immunotolerance treatment. The latter two patients are AIDS and ARC free so far, but patient No. 2 developed a mild-to-severe thrombocytopenia.Considering the high cost of the treatment and the possibility that such an intensive administration of FVIII concentrates might worsen the immunological status of patients, this therapeutic procedure should only be applied with caution.
Collapse
Affiliation(s)
- G Mariani
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| | - S Solinas
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| | - D Pasqualetti
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| | - A Ghirardini
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| | - P Verani
- Laboratorio di Virologia, Instituto Superiore di Sanita' Roma, Italy
| | - S Buttó
- Laboratorio di Virologia, Instituto Superiore di Sanita' Roma, Italy
| | - M Lopez
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| | - T Moretti
- Dipartimento di Biopatologia Umana, Sezione di Ematologia Universita' di Roma “La Sapienza”, Roma, Italy
| |
Collapse
|
19
|
Ghirardini A, Mariani G, lacopino G, Tirindelli MC, Solinas S, Moretti T. Concentrated DDAVP: Further Improvement in the Management of Mild Factor VIII Deficiencies. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study was carried out to evaluate the pharmacological efficacy of a new concentrated 1 Deamino - (8-D-arginine) - vasopressin (DDAVP) preparation. Concentrated DDAVP (C- DDAVP), (40 μg/mL) was given subcutaneously (s.c.) in hemophilia and von Willebrand Disease (vWD), and the response was evaluated in terms of factor VIII/vWF (VUI/von Willebrand Factor) complex response. This response was also compared to that obtained using the currently available commercial preparation (4 μg/mL) given either s.c. or intravenously (i. v.). The maximal f. VIII response after s.c. C-DDAVP was reached one hour after the injection (x:3.6 times the resting values) with an average decline of 15% at two hours. The response to s.c. C- DDAVP in patients with hemophilia was slightly better than thut obtained with the diluted brand, but the difference did not reach any statistical significance even when the schedules were compared in the same patients. In type I (placed normal subtype) vWD, a higher response in terms of factor VIII :C increase in comparison with hemophiliacs was obtained. Doth Ristocetin cofactor activity (RiCof) and bleeding time responded to this vasopressin analogue, when administered subcutaneously.
Collapse
Affiliation(s)
- A Ghirardini
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| | - G Mariani
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| | - G lacopino
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| | - M C Tirindelli
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| | - S Solinas
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| | - T Moretti
- The Department of Human Biopathology, Section of Hematology, University of Roma “La Sapienza”, Rome, Italy
| |
Collapse
|
20
|
Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2018; 28:3028-3036. [PMID: 29045535 PMCID: PMC5834012 DOI: 10.1093/annonc/mdx628] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. Patients and methods Patients who had disease progression after first-line anti-cancer therapy were randomized (2 : 2 : 1) to selumetinib 75 mg b.i.d. plus docetaxel 60 or 75 mg/m2 (SEL + DOC 60; SEL + DOC 75), or placebo plus docetaxel 75 mg/m2 (PBO + DOC 75). Patients were initially enrolled independently of KRAS mutation status, but the protocol was amended to include only patients with centrally confirmed KRAS wild-type NSCLC. Primary end point was progression-free survival (PFS; RECIST 1.1); statistical analyses compared each selumetinib group with PBO + DOC 75 for KRAS wild-type and overall (KRAS mutant or wild-type) populations. Results A total of 212 patients were randomized; 69% were KRAS wild-type. There were no statistically significant improvements in PFS or overall survival for overall or KRAS wild-type populations in either selumetinib group compared with PBO + DOC 75. Overall population median PFS for SEL + DOC 60, SEL + DOC 75 compared with PBO + DOC 75 was 3.0, 4.2, and 4.3 months, HRs: 1.12 (90% CI: 0.8, 1.61) and 0.92 (90% CI: 0.65, 1.31), respectively. In the overall population, a higher objective response rate (ORR; investigator assessed) was observed for SEL + DOC 75 (33%) compared with PBO + DOC 75 (14%); odds ratio: 3.26 (90% CI: 1.47, 7.95). Overall the tolerability profile of SEL + DOC was consistent with historical data, without new or unexpected safety concerns identified. Conclusion The primary end point (PFS) was not met. The higher ORR with SEL + DOC 75 did not translate into prolonged PFS for the overall or KRAS wild-type patient populations. No clinical benefit was observed with SEL + DOC in KRAS wild-type patients compared with docetaxel alone. No unexpected safety concerns were reported. Trial identifier Clinicaltrials.gov NCT01750281.
Collapse
Affiliation(s)
- J-C Soria
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - A Fülöp
- Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf (M.R.), Germany
| | - C Maciel
- Department of Electrical Engineering, University of São Paulo, São Carlos, São Paulo, Brazil
| | - J R Fischer
- Department of Internal Medicine II, Lungenklinik Löwenstein GmbH, Löwenstein, Germany
| | - G Girotto
- Department of Medical Oncology, Centro Integrado de Pesquisa, Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto
| | - S Lago
- Department of Oncology, Serviço de Oncologia do Hospital São Lucas da PUCRS, Porto Alegre, Brazil
| | - E Smit
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - G Ostoros
- Department of Tumor Biology, National Koranyi Institute of Pulmonology, Budapest, Hungary
| | - W E E Eberhardt
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Ruhrlandklinik, University Duisburg-Essen, Essen, Germany
| | - P Lishkovska
- Department of Medical Oncology, Individualna Praktika Za Spetsializirana Meditsinska Pomosht, Vratsa, Bulgaria
| | | | | | | | | | | | | | | | | | - P A Jänne
- Lowe Center for Thoracic Oncology and The Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
21
|
Trecate G, Ceglia E, Stabile F, Tesoro-Tess JD, Mariani G, Zambetti M, Musumeci R. Locally Advanced Breast Cancer Treated with Primary Chemotherapy: Comparison between Magnetic Resonance Imaging and Pathologic Evaluation of Residual Disease. Tumori 2018; 85:220-8. [PMID: 10587021 DOI: 10.1177/030089169908500402] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background We evaluated the response of locally advanced breast cancer to induction chemotherapy using MRI techniques. The size and vitality of any residual pathologic tissue was quantified by means of morphologic and dynamic analysis. A curve derived from the dynamic parameters shows the uptake intensity with respect to the time elapsed since administration, which is related to vascularization and therefore indirectly reflects the angiogenesis of malignant tissue. Methods and Study Design A group of 30 patients were examined with MRI for staging purposes before undergoing treatment and subsequently to assess the response to treatment. Alterations in size and dynamic parameters were closely monitored. Results The overall accuracy was 90%, the sensitivity 96%, the specificity 75%, the positive predictive value 92.5% and the negative predictive value 66%. Interestingly, analysis of the dynamic curves made it possible to obtain additional information regarding the angiogenetic activity of the residual tumor. Conclusions Evaluation of the response to treatment by means of conventional imaging and clinical examination can be particularly difficult because of the fibrosis induced by cytotoxic drugs or the small volume of residual disease. The additional information supplied by MRI could therefore allow a more conservative surgical approach in selected cases of optimal response to treatment, as well as a much more accurate follow-up. Furthermore, the variation in dynamic parameters according to the vitality of residual disease could in the future become a useful tool for monitoring the effectiveness of anti-angiogenetic drugs.
Collapse
Affiliation(s)
- G Trecate
- Divisione di Radiodiagnostica E, Istituto Nazionale Tumori, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
22
|
Gonella M, Fanara G, Buzzigoli G, Bartolini V, Mariani G. Serum Phosphate Concentration with Relation to the Hematocrit Value in Uremic Patients on Chronic Hemodialysis. Int J Artif Organs 2018. [DOI: 10.1177/039139888400700610] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- M. Gonella
- Division of Nephrology of the Hospital of Pisa, and C.N.R. Institute of Clinical Physiology at the University of Pisa, Pisa (Italy)
| | - G. Fanara
- Division of Nephrology of the Hospital of Pisa, and C.N.R. Institute of Clinical Physiology at the University of Pisa, Pisa (Italy)
| | - G. Buzzigoli
- Division of Nephrology of the Hospital of Pisa, and C.N.R. Institute of Clinical Physiology at the University of Pisa, Pisa (Italy)
| | - V. Bartolini
- Division of Nephrology of the Hospital of Pisa, and C.N.R. Institute of Clinical Physiology at the University of Pisa, Pisa (Italy)
| | - G. Mariani
- Division of Nephrology of the Hospital of Pisa, and C.N.R. Institute of Clinical Physiology at the University of Pisa, Pisa (Italy)
| |
Collapse
|
23
|
Villa G, Gipponi M, Buffoni F, Vecchio C, Bianchi P, Agnese G, Di Somma C, Catturich A, Rosato F, Tomei D, Nicolò G, Badellino F, Mariani G, Canavese G. Localization of the Sentinel Lymph Node in Breast Cancer by Combined Lymphoscintigraphy, Blue DYE and Intraoperative Gamma Probe. Tumori 2018; 86:297-9. [PMID: 11016707 DOI: 10.1177/030089160008600408] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Axillary lymph node status represents the most important prognostic factor in patients with operable breast cancer. A severe limitation of this technique is the relatively high rate of false negative sentinel lymph nodes (>5%). We studied 284 patients suffering from breast cancer; 264 had T1 tumors (16 T1a, 37 T1b and 211 T1c), while 20 had T2 tumors. All patients underwent lymphoscintigraphy 18-h before surgery. At surgery, 0.5 mL of patent blue violet was injected subdermally, and the sentinel lymph node (SN) was searched by gamma probe and by the dye method. The surgically isolated SN was processed for intraoperative and delayed examinations. The SN was successfully identified by the combined radioisotopic procedure and patent blue dye technique in 278/284 cases (97.9%). Analysis of the predictive value of the SN in relation to the status of the axillary lymph nodes was limited to 191 patients undergoing standard axillary dissection irrespective of the SN status. Overall, 63/191 (33%) identified SNs were metastatic, the SN alone being involved in 37/63 (58.7%) patients; a positive axillary status with negative SN was found in 10/73 (13.7%) patients with metastatic involvement. In T1a-T1b patients the SN turned out to be metastatic in 9/53 patients (17.0%). In 7/9 patients the SN was the only site of metastasis, while in 2/9 patients other axillary lymph nodes were found to be metastatic in addition to the SN. None of the 44 patients in whom the SN proved to be non-metastatic showed any metastatic involvement of other axillary lymph nodes. Our results demonstrate a good predictive value of SN biopsy in patients with breast cancer; the predictive value was excellent in those subjects with nodules smaller than 1 cm.
Collapse
Affiliation(s)
- G Villa
- Nuclear Medicine Service, DIMI, University of Genoa Medical School, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Villa G, Agnese G, Bianchi P, Buffoni F, Costa R, Carli F, Peressini A, Solari N, Cafiero F, Mariani G. Mapping the Sentinel Lymph Node in Malignant Melanoma by Blue Dye, Lymphoscintigraphy and Intraoperative Gamma Probe. Tumori 2018; 86:343-5. [PMID: 11016724 DOI: 10.1177/030089160008600425] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Eighty-eight consecutive patients (48 men and 40 women; mean age, 58.9 years; range, 16–84 years) with clinically localized cutaneous melanoma involving the trunk, extremities or head and neck underwent lymphatic mapping at our institution. The primary melanoma had a mean thickness of 2.74 mm (range, 0.95 to 9 mm). Patients were divided into two groups: group A (39 patients) underwent only vital blue dye (VBD) mapping, while group B (49 patients) underwent lymphatic mapping with VBD and radio-guided surgery (RGS) combined. In all patients 1-1.5 mL of VBD was injected subdermally around the biopsy scar 10–20 min before surgery. In group B 37 MBq in 150 μL of 99mTc-HSA nanocolloid was additionally injected intradermally 18 h before surgery (3–6 aliquots injected perilesionally). In all lymphatic basins where drainage was noted the sentinel lymph nodes (SNs) were identified and marked with a cutaneous marker. Final identification of the SN was then performed externally by a hand-held gamma probe. After the induction of anesthesia 0.5–1-0 mL of patent blue V dye was injected intradermally with a 25-gauge needle around the site of the primary melanoma. SNs were examined by routine hematoxylin and eosin (H&E) staining and immunohistochemistry. Patients with histologically positive SN(s) underwent standard lymph node dissection (SLND) in the involved lymph node basin. The SN was identified in 37/39 patients (94.9%) of group A and in 48/49 patients (98.0%) of group B. Blue dye mapping failed to identify the SN in 5 of the 88 patients (5.8%), while the radioisotope method failed in only 1 of 49 patients (2.0%). Similar results were obtained with the combined use of the two probes. The average number of SNs harvested was 1.9 per basin sampled, which does not differ significantly from the numbers reported by other authors114. The SN was histologically positive in 18 patients (20.5%). None of the 12 patients with a Breslow thickness less than 1.5 mm had positive SNs, whereas 18 of the 77 patients (23.4%) with a Breslow index exceeding 1.5 mm showed metastatic SNs with H&E or immunohistochemistry. The latter all underwent SLND of the affected basin. In 10 patients (55.6%) the SN was the only site of tumor invasion; eight patients (44.4%) with positive SNs had one or more metastatic lymph nodes in the draining basin.
Collapse
Affiliation(s)
- G Villa
- Nuclear Medicine Service, DIMI, Genoa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
Rationale and objectives To review magnetic resonance imaging (MRI) findings in lobular breast carcinoma, the in situ or infiltrating subtype, with special attention to the dynamic curves with the aim to evaluate possible differences with ductal carcinoma. Methods In 2 years, 27 patients with lobular and one with tubular carcinoma underwent MRI at the Istituto Nazionale Tumori of Milan. Results All lobular carcinomas demonstrated early or late enhancement (100% sensitivity), without significant differences in morphology compared with ductal carcinoma, but frequently with a different shape of the dynamic curves. Conclusions Due to its infiltrative growth associated to only limited connective tissue reaction, lobular carcinoma often encounters difficulties in mammographic diagnosis. In contrast, MRI can be very helpful in evaluating the true extension of the disease, especially when breast conservation is considered. Due to a more consistent fibrotic stroma, these lesions sometimes show a delayed enhancement, which suggests that more than one set of subtracted images should be evaluated during MRI analysis.
Collapse
Affiliation(s)
- G Trecate
- Unit of Diagnostic Radiology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
26
|
Gonella M, Fanara G, Maccheroni M, Mariani G. Serum Creatinine (sCr) Changes Induced by Hemodialysis (HD) with Relation to the Plasma Volume/Hematocrit Ratio (PV/Ht). Int J Artif Organs 2018. [DOI: 10.1177/039139888200500113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- M. Gonella
- Division of Nephrology of the Hospital of Pisa, and 5th Medical Pathology of the University of Pisa, Pisa (Italy)
| | - G. Fanara
- Division of Nephrology of the Hospital of Pisa, and 5th Medical Pathology of the University of Pisa, Pisa (Italy)
| | - M. Maccheroni
- Division of Nephrology of the Hospital of Pisa, and 5th Medical Pathology of the University of Pisa, Pisa (Italy)
| | - G. Mariani
- Division of Nephrology of the Hospital of Pisa, and 5th Medical Pathology of the University of Pisa, Pisa (Italy)
| |
Collapse
|
27
|
Kutz A, Mariani G, Schweins R, Streb C, Gröhn F. Self-assembled polyoxometalate-dendrimer structures for selective photocatalysis. Nanoscale 2018; 10:914-920. [PMID: 29177296 DOI: 10.1039/c7nr07097g] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We present a novel, self-assembled nanostructure with selective photocatalytic activity formed from anionic polyoxometalate clusters and cationic dendrimers by electrostatic self-assembly. The association of the components in aqueous solution is driven by ionic interaction and steric factors yielding stable aggregates of a defined size with a coil-like structure. The assemblies show high potential for the application in solar-energy conversion systems due to their enhanced and substrate specific photocatalytic activity.
Collapse
Affiliation(s)
- A Kutz
- Department of Chemistry and Pharmacy, Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander Universität Erlangen-Nürnberg, Egerlandstr. 3, 91058 Erlangen, Germany.
| | | | | | | | | |
Collapse
|
28
|
Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Corrigendum: Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod 2018; 33:178. [PMID: 29177428 DOI: 10.1093/humrep/dex353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Accepted: 11/06/2017] [Indexed: 11/12/2022] Open
Affiliation(s)
- E Labarta
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
| | - G Mariani
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
| | - N Holtmann
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
- Current address: Department of Obstetrics and Gynecology, Heinrich Heine University Medical Center, Moorenstrasse 5, 40225 Düsseldorf, Germany
| | - P Celada
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
| | - J Remohi
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
| | - E Bosch
- Department of Human Reproduction, Instituto Valenciano de Infertilidad, Plaza Policía Local 3, Valencia 46015, Spain
| |
Collapse
|
29
|
Mariani G, Pelizzo MR, Rubello D. Minimally invasive radio-guided parathyroidectomy on a group of 452 primary hyperparathyroid patients. Nuklearmedizin 2017. [DOI: 10.1160/nukmed-0036] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryThe aim of this study was to investigate the efficacy of minimally invasive radio-guided parathyroidectomy (MIRP) in primary hyperparathyroid (PHPT) patients. Patients, methods: 452 consecutive PHPT patients were evaluated. Inclusion criteria for MIRP were (a) evidence at scintigraphy of a solitary parathyroid adenoma (PA); (b) a clear sestamibi uptake in the PA; (c) the absence of concomitant thyroid nodules; (d) no history of familial HPT or MEN; (e) no history of previous neck irradiation. Intra-operative protocol consisted of the injection of a low 37 MBq sestamibi dose in the operating suite 10 min before surgery. A hand held 11-mm collimated gamma probe was used. Quick PTH (QPTH) was routinely measured. Results: 344 out of the 452 patients met the inclusion criteria, and MIRP was successfully performed in 321 of them (93.3%). No major intra-operative complication was recorded. MIRP required a mean operative time of 32 min, and a mean hospital stay of 1.2 d. The parathyroid to background ratio (P/B) calculated by the probe was well correlated with the P/B calculated by sestamibi SPECT (r = 0.91; p <0.01), while no significant correlation was found between the probe-calculated P/B and the P/B calculated at planar sestamibi scan. Conclusions: In our experience: a) an accurate preoperative localising imaging protocol based on planar and SPECT sestamibi scan, and neck US is effective in selecting PHPT patients for MIRP, b) the P/B calculated by sestamibi SPECT seems able to predict the probe-calculated P/B more accurately than the P/B calculated at planar scan, c) the low 37 MBq sestamibi dose protocol proved to be a safe and effective approach to perform MIRP.
Collapse
|
30
|
Gringeri A, Peyvandi F, Di Paolantonio T, Mariani G, Mannucci P. Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1612997] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Donnini I, Rinnoci V, Nannucci S, Valenti R, Pescini F, Mariani G, Bianchi S, Dotti MT, Federico A, Inzitari D, Pantoni L. Pregnancy in CADASIL. Acta Neurol Scand 2017; 136:668-671. [PMID: 28608406 DOI: 10.1111/ane.12784] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2017] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease caused by NOTCH3 gene mutations. CADASIL women are frequently considered at high risk of systemic vascular events during pregnancy and often prescribed with antithrombotic drugs. This decision is not evidence-based considering the lack of data about pregnancy outcome in CADASIL. We describe our experience on pregnancy in CADASIL patients. MATERIALS AND METHODS We reviewed records of 50 CADASIL females followed in our center, and we collected prospective information in six patients for a total of 93 pregnancies. RESULTS No woman had the disease onset or suffered from cerebral vascular ischemic events during pregnancy. Sixteen miscarriages (17.2%) were recorded. There were 72 vaginal births, and five cesarean sections. Considering the six patients followed prospectively (for a total of eight pregnancies), data on fetal growth and newborns weight were in line with those from the general population. Considering gestational complications, we recorded mild proteinuria without hypertension in one patient and hyperinsulinemia and pre-eclampsia in another affected by a known nephropathy. Antithrombotic drugs were used in three patients, in one for an unrelated coexisting prothrombotic condition. CONCLUSIONS CADASIL does not seem to be associated with an unfavorable outcome of pregnancy either for women and fetuses. Patients and treating physicians should be reassured that pregnancy can be safely initiated in CADASIL, as there is no evidence to support a specific preventive antithrombotic treatment during pregnancy in CADASIL. Larger studies are needed to definitively confirm these conclusions.
Collapse
Affiliation(s)
- I. Donnini
- NEUROFARBA Department; University of Florence; Florence Italy
| | - V. Rinnoci
- NEUROFARBA Department; University of Florence; Florence Italy
| | - S. Nannucci
- NEUROFARBA Department; University of Florence; Florence Italy
- Department of Emergency Neurology; C. Mondino National Neurological Institute; Pavia Italy
| | - R. Valenti
- NEUROFARBA Department; University of Florence; Florence Italy
| | - F. Pescini
- Stroke Unit; Emergency Department; Azienda Ospedaliero Universitaria Careggi; Florence Italy
| | - G. Mariani
- Gynecology and Obstetrics Department; University of Florence; Florence Italy
| | - S. Bianchi
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - M. T. Dotti
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - A. Federico
- Department of Medical Surgical and Neurological Sciences; University of Siena; Siena Italy
| | - D. Inzitari
- NEUROFARBA Department; University of Florence; Florence Italy
| | - L. Pantoni
- NEUROFARBA Department; University of Florence; Florence Italy
| |
Collapse
|
32
|
Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod 2017; 32:2437-2442. [DOI: 10.1093/humrep/dex316] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Accepted: 09/28/2017] [Indexed: 11/14/2022] Open
|
33
|
Vernieri C, Milano M, Mennitto A, Fucà G, Rinaldi L, Ferrari B, Capri G, Mariani G, Bianchi G, Longo V, de Braud F. Safety and metabolic effects of the fasting mimicking diet in cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx436.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Mariani G, Galli G, Cavalieri S, Valagussa P, Bianchi G, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
|
36
|
Generali D, Bordonaro R, Febbraro A, Madoffa A, Romito S, Michelotti A, Savastano C, Mariani G, Tondini C, Piovano P, Iona MT, Bighin C, Roviello G, Ascione G, Goffredo F, Sartori D, Frassoldati A, Simoncini E. Abstract P4-22-17: Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access “BALLET” study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The expanded access “BALLET” study has been designed toevaluate the safety of EVE plus EXE combination in hormone receptor-positive (HR+), human epidermal growth factor-receptor-2-negative (HER2-) metastatic Breast Cancer (mBC). The Italian population was predominantly enrolled in trial.
Patients and methods: Patients has been included according to the inclusion and exclusion criteria provided previously in the BALLET study. The aim of our analysis was the safety everolimus and exemestane analysed in two sets of population: a subpopulation including only patients who never received chemotherapy in metastatic setting (416 patients – 36.1% of the safety population) and a subpopulation including only patients who received at least one chemotherapy in metastatic setting, whatever the line of treatment (735 patients – 63.9%).
Results:One thousand two hundred seventy nine (1279) Italian female patients were screened, 1153 (90.1% of the screened set) out of these were included in the analysis and 1151 (90.0% of the screened set) were included in the safety population. 1116 (97.0% of the safety population) prematurely discontinued the study drug and the main reasons reported were disease progression (39.1%), local reimbursement of everolimus (31.1%) and adverse event(s) (16.1%). The mean duration of study treatment exposure was 158.3±106.79 days (median 139.5) for exemestane and 153.9±108.48 days (median 135.0) for everolimus with a treatment compliance (higher than 90%) of 94.4% and 58.6% and (lower than 60%) of 0.1% and 15.1% for exemestane and everolimus, respectively. 92.5% of patients of the safety population (91.1% and . 93.3% patients without and with chemotherapy respectively) experienced at least one adverse event: gastrointestinal disorders” (67.3% vs. 64.6% in without and with chemo group); general disorders (48.6% vs. 48.3%); metabolism and nutrition disorders (35.6% vs. 37.4%) and skin and subcutaneous tissue disorders (32.2% vs. 27.5%). The incidence of everolimus related adverse events was higher (83.9%) when compared to those which occurred with exemestane. The most commonly reported adverse event was stomatitis (51.3% of patients) with 22.5% Grade 1; 18.2% Grade 2; 10.5% Grade 3; 0.2% Grade 4. The 49.7% of the patients experienced at least one stomatitis related to everolimus. No relevant difference was observed between the two groups of patients without and with chemo in metastatic setting.
Conclusions: The administration of chemotherapy before starting EVE plus EXE combination did not affect the safety profile of EXE/EVE in the treatment of mBC. The stomatitis is the most frequent and relevant adverse event to be clinically focused on.
Citation Format: Generali D, Bordonaro R, Febbraro A, Madoffa A, Romito S, Michelotti A, Savastano C, Mariani G, Tondini C, Piovano P, Iona MT, Bighin C, Roviello G, Ascione G, Goffredo F, Sartori D, Frassoldati A, Simoncini E. Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access “BALLET” study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-17.
Collapse
|
37
|
Jänne P, van den Heuvel M, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile D, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.46] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Dymond A, Elks C, Martin P, Carlile D, Mariani G, Lovick S, Huang Y, Lorch U, Brown H, So K. Pharmacokinetics (PK) and pharmacogenetics (PG) of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VCG, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Ann Oncol 2016; 27:1719-25. [PMID: 27358383 DOI: 10.1093/annonc/mdw249] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Accepted: 06/13/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This European phase IIIb, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a patient population similar to BOLERO-2. PATIENTS AND METHODS Post-menopausal women aged ≥18 years with hormone receptor-positive, human epidermal growth factor-receptor-2-negative advanced breast cancer (ABC) recurring/progressing during/after prior non-steroidal aromatase inhibitors were enrolled. The primary objective was safety of EVE plus EXE based on frequency of adverse events (AEs), and serious AEs (SAEs). The secondary objective was to evaluate AEs of grade 3/4 severity. RESULTS The median treatment duration was 5.1 months [95% confidence interval (CI) 4.8-5.6] for EVE and 5.3 months (95% CI 4.8-5.6) for EXE. Overall, 2131 patients were included in the analysis; 81.8% of patients experienced EVE- or EXE-related or EVE/EXE-related AEs (investigator assessed); 27.2% were of grade 3/4 severity. The most frequently reported non-hematologic AEs were (overall %, % EVE-related) stomatitis (52.8%; 50.8%) and asthenia (22.8%; 14.6%). The most frequently reported hematologic AEs were (overall %, % EVE-related) anemia (14.4%; 8.1%) and thrombocytopenia (5.9%; 4.6%). AE-related treatment discontinuations were higher in elderly (≥70 years) versus non-elderly patients (23.8% versus 13.0%). The incidence of EVE-related AEs in both elderly and non-elderly patients appeared to be lower in first-line ABC versus later lines. The incidence of AEs (including stomatitis/pneumonitis) was independent of BMI status (post hoc analysis). Overall, 8.5% of patients experienced at least one EVE-related SAE. Of the 121 on-treatment deaths (5.7%), 66 (3.1%) deaths were due to disease progression and 46 (2.2%) due to AEs; 4 deaths were suspected to be EVE-related. CONCLUSIONS This is the largest ever reported safety dataset on a general patient population presenting ABC treated with EVE plus EXE and included a sizeable elderly subset. Although the patients were more heavily pretreated, the safety profile of EVE plus EXE in BALLET was consistent with BOLERO-2. CLINICAL TRIAL REGISTRATION EudraCT Number: 2012-000073-23.
Collapse
Affiliation(s)
- G Jerusalem
- Department of Medical Oncology, CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium
| | - G Mariani
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - E M Ciruelos
- Medical Oncology Department, Breast Cancer Unit, University Hospital 12 de Octubre, Madrid, Spain
| | - M Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Univesidad Complutense, Madrid, Spain
| | - V C G Tjan-Heijnen
- Department of Medical Oncology, GROW, Maastricht University Medical Centre, Maastricht, The Netherlands
| | - P Neven
- KULeuven (University of Leuven), Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, Belgium
| | - J G Gavila
- Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain
| | - A Michelotti
- UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy
| | - F Montemurro
- Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia, Institute of Candiolo Cancer Center (IRCCs), Candiolo, Torino, Italy
| | - D Generali
- Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy
| | - E Simoncini
- Breast Unit, Azienda Ospedaliera Spedali Civili, Brescia, Italy
| | - I Lang
- Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
| | - J Mardiak
- Narodny Onkologicky Ustav Klenova 1, Bratislava, Slovakia
| | - B Naume
- Department of Oncology, Oslo University Hospital, Oslo, Norway K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - M Camozzi
- Novartis Farma S.p.A., Origgio, VA, Italy
| | - K Lorizzo
- Novartis Farma S.p.A., Origgio, VA, Italy
| | | | - P Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy Medical Oncology 2, Istituto Oncologico Veneto, Padova, Italy
| |
Collapse
|
40
|
Napolitano M, Di Minno MND, Batorova A, Dolce A, Giansily-Blaizot M, Ingerslev J, Schved JF, Auerswald G, Kenet G, Karimi M, Shamsi T, Ruiz de Sáez A, Dolatkhah R, Chuansumrit A, Bertrand MA, Mariani G. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia 2016; 22:752-9. [PMID: 27338009 DOI: 10.1111/hae.12978] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/18/2016] [Indexed: 12/01/2022]
Abstract
INTRODUCTION A paucity of data exists on the incidence, diagnosis and treatment of bleeding in women with inherited factor VII (FVII) deficiency. AIM Here we report results of a comprehensive analysis from two international registries of patients with inherited FVII deficiency, depicting the clinical picture of this disorder in women and describing any gender-related differences. METHODS A comprehensive analysis of two fully compatible, international registries of patients with inherited FVII deficiency (International Registry of Factor VII deficiency, IRF7; Seven Treatment Evaluation Registry, STER) was performed. RESULTS In our cohort (N = 449; 215 male, 234 female), the higher prevalence of mucocutaneous bleeds in females strongly predicted ensuing gynaecological bleeding (hazard ratio = 12.8, 95% CI 1.68-97.6, P = 0.014). Menorrhagia was the most prevalent type of bleeding (46.4% of patients), and was the presentation symptom in 12% of cases. Replacement therapies administered were also analysed. For surgical procedures (n = 50), a receiver operator characteristic analysis showed that the minimal first dose of rFVIIa to avoid postsurgical bleeding during the first 24 hours was 22 μg kg(-1) , and no less than two administrations. Prophylaxis was reported in 25 women with excellent or effective outcomes when performed with a total weekly rFVIIa dose of 90 μg kg(-1) (divided as three doses). CONCLUSION Women with FVII deficiency have a bleeding disorder mainly characterized by mucocutaneous bleeds, which predicts an increased risk of ensuing gynaecological bleeding. Systematic replacement therapy or long-term prophylaxis with rFVIIa may reduce the impact of menorrhagia on the reproductive system, iron loss and may avoid unnecessary hysterectomies.
Collapse
Affiliation(s)
- M Napolitano
- Haematology Unit, Thrombosis and Hemostasis Reference Regional Center, University of Palermo, Palermo, Italy.
| | - M N D Di Minno
- Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy
| | - A Batorova
- The National Haemophilia Centre, Institute of Haematology and Blood Transfusion, School of Medicine of Comenius University, University Hospital, Bratislava, Slovakia
| | - A Dolce
- National Institute of Statistics, Palermo, Italy
| | | | - J Ingerslev
- Centre for Haemophilia & Thrombosis, University Hospital Skejby, Aarhus, Denmark
| | - J-F Schved
- Laboratory of Haematology, University Hospital, Montpellier, France
| | - G Auerswald
- Klinikum Bremen-Mitte, Prof.-Hess Kinderklinik, Bremen, Germany
| | - G Kenet
- National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M Karimi
- Haematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - T Shamsi
- National Institute of Blood Diseases & Bone Marrow Transplantation, Karachi, Pakistan
| | - A Ruiz de Sáez
- Centro Nacional de Hemophilia, Banco Municipal de Sangre, Caracas, Venezuela
| | - R Dolatkhah
- Haematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - A Chuansumrit
- Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | | |
Collapse
|
41
|
Ciruelos EM, Jerusalem G, Generali D, Lang I, Gavila JG, Michelotti A, Tjan-Heijnn VCG, Mariani G, Conte P, Beliera A, Camozzi M, Lorizzo K, Martin M. Abstract P4-13-10: Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC) in the BALLET trial (CRAD001YIC04). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Stomatitis is the most common adverse event (AE) associated with mTOR inhibitors, including EVE. In the pivotal BOLERO-2 trial, stomatitis was reported for 59% vs 12% (Gr3, 8% vs <1%) of pts with HR+, HER2– ABC who received EVE + EXE vs EXE alone. Of the limited real world evidence available, the BRAWO trial showed a stomatitis incidence of 39.8% (Gr3, 3.4%) in a similar pt population. Additional data are warranted to better understand the stomatitis incidence and time-course in order to minimize treatment discontinuations.
Methods
BALLET is a Phase 3b, European, multi-center, open-label, single-arm, expanded-access study that evaluated safety of EVE (10 mg/d) and EXE (25 mg/d) in 2131 postmenopausal women with HR+, HER2– ABC that progressed on prior NSAI treatment. Primary endpoint was safety; secondary endpoint was characterization of grade 3/4 AEs. In this exploratory analysis, we split the pts in two groups based on having experienced at least one all grade stomatitis event in the first 8 wks (cut-off chosen based on reports that 89.4% of stomatitis events occurred within 8 wks of EVE initiation [Rugo, ASCO 2014]) vs none.
Results
This subgroup analysis included 919 pts with stomatitis (43.1% of the full population). Baseline pt characteristics were comparable to the overall study population, except for more comorbidity (cardiovascular and metabolic disorder) in stomatitis subset. Pts with stomatitis had a longer EVE treatment duration vs pts who didn't (5.8 mo [95%CI, 5.0-6.2] vs 4.7 mo [95%CI, 4.4-5.3]; hazard ratio, 1.121 [95%CI, 0.97-1.28] censored by pts who switched to commercial drug). The relative risk of initial onset of stomatitis at 6 wks was ∼40%; median time to onset was 28 days. Majority of stomatitis events were of grade 1/2 severity (80%); grade 3/4 stomatitis was reported for 20% of pts. Most frequent reasons for treatment discontinuation in pts with stomatitis were reimbursement (37.6%), disease progression (35.0%), and AEs (16.2%). Most frequent AEs which led to treatment discontinuation in these pts were stomatitis in 3.7% (Grade 3/4, 2%), pneumonitis in 2.9% (Grade 3/4, 1.3%) and asthenia in 1.8% (Grade 3/4, 1%). Median EVE relative dose intensity in pts with stomatitis was 0.92. In the stomatitis subset, dose interruptions and reductions were required for 66.7% and 37.6% of pts, respectively; most frequent reasons for dose adjustments were AEs (65.9%) which included stomatitis (46.8%), asthenia (6.3%), and pneumonitis (5.3%). Median time to first dose modification in pts with stomatitis was 30 days; median duration of dose interruptions was 16 days. On-treatment deaths (4.4%) were due to progressive disease (2.1%), AEs (1.7%), and other reasons (0.5%).
Conclusions
These results confirmed the stomatitis time-course observed previously and that the majority of these events are of low grade. Stomatitis was the most common cause of dose reductions and interruptions due to AEs and was manageable with dose adjustments; there was a positive association between stomatitis and longer treatment duration. Therefore, proactive management, diligent monitoring and appropriate dose modifications, are recommended to keep pts on treatment.
Citation Format: Ciruelos EM, Jerusalem G, Generali D, Lang I, Gavila JG, Michelotti A, Tjan-Heijnn VCG, Mariani G, Conte P, Beliera A, Camozzi M, Lorizzo K, Martin M. Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC) in the BALLET trial (CRAD001YIC04). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-10.
Collapse
Affiliation(s)
- EM Ciruelos
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - G Jerusalem
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D Generali
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - I Lang
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - JG Gavila
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - A Michelotti
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - VCG Tjan-Heijnn
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - G Mariani
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - P Conte
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - A Beliera
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Camozzi
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - K Lorizzo
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Martin
- Breast Cancer Unit, University Hospital, Madrid, Spain; CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium; U.O. Multidisciplinare di Patologia Mammaria U.S. Terapia Molecolare e Farmacogenomica AZ. Istituti Ospitalieri di Cremona Viale Concordia, Cremona, Italy; National Institute of Oncology, Budapest, Hungary; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy; Maastricht University Medical Centre, Maastricht, Netherlands; Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, via Gattamelata, Padova, Italy; Novartis Farma, Madrid, Spain; Novartis Farma, Origgio/VA, Italy; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
42
|
Napolitano M, Dolce A, Batorova A, Giansily-Blaizot M, Ingerslev J, Mirbehbahani N, Di Minno MND, Lopez Fernandez MF, Karimi M, Charoenkwan P, Kavakli K, Mariani G. Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery. Haemophilia 2015; 21:e513-e517. [PMID: 26249164 DOI: 10.1111/hae.12782] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/03/2015] [Indexed: 06/04/2023]
Affiliation(s)
- M Napolitano
- Haematology Unit, Thrombosis and Hemostasis Reference Regional Center, Università di Palermo, Palermo, Italy
| | - A Dolce
- National Institute of Statistics, Palermo, Italy
| | - A Batorova
- The National Haemophilia Centre, Institute of Haematology and Blood Transfusion, University Hospital, Bratislava, Slovakia
| | | | - J Ingerslev
- Centre for Haemophilia & Thrombosis, University Hospital Skejby, Aarhus, Denmark
| | - N Mirbehbahani
- Hematology and Oncology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - M N D Di Minno
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | | | - M Karimi
- Haematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - P Charoenkwan
- Division of Hematology, Chiang Mai University, Chiang Mai, Thailand
| | - K Kavakli
- Children's Hospital, Ege University Faculty of Medicine, Izmir, Turkey
| | - G Mariani
- Università di Ferrara Medical School, Ferrara, Italy
| |
Collapse
|
43
|
Avanzini F, Mafrici A, Riva E, Franzosi MG, Milani V, Giudici V, Marelli G, Mariani G, Piatti PM, Roncaglioni MC. A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome. Nutr Metab Cardiovasc Dis 2015; 25:916-923. [PMID: 26298425 DOI: 10.1016/j.numecd.2015.07.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Revised: 07/14/2015] [Accepted: 07/19/2015] [Indexed: 02/07/2023]
Abstract
AIM To assess the prevalence, risk and management of hyperglycemia in patients with acute coronary syndrome (ACS). DESIGN a multicenter prospective observational study of a representative sample of patients with ACS consecutively admitted to intensive cardiac care units (ICCU). SETTING 31 out of 61 ICCUs in Lombardy, the most heavily populated Italian region. From May 2009 to April 2010 1260 patients (69.4% male; mean age 68 ± 13 years) were included in the study: 301 (23.9%) were known diabetic patients (D) and 265 (21.0%) had hyperglycemia (H) (blood glucose >180 mg/dL) at hospital admission, 174 with a history of diabetes (D+H+) and 91 without (D-H+). On the first day after admission intravenous insulin infusion was prescribed to 72 D+H+ (41.4%) and 10 D-H+ (11.0%), according to different protocols. Approximately one third of D+H+ patients (59) and one fifth (17) of D-H+ maintained mean blood glucose higher than 180 mg/dL during the first day in the ICCU. Patients with diabetes or hyperglycemia had a higher incidence of major adverse cardiovascular events or death in hospital. However, at multivariable analysis neither diabetes nor blood glucose at admission was associated with a poor prognosis whereas mean blood glucose on the first day was an independent negative prognostic predictor (OR 1.010, 95% CI 1.002-1.018, p = 0.016). CONCLUSION Hyperglycemia is frequent in patients with ACS and is independently associated with a poor in-hospital prognosis if it persists in first day. Unfortunately, however, this condition is still poorly treated, with far from optimal blood glucose control.
Collapse
Affiliation(s)
- F Avanzini
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Desio Hospital, Desio, Italy.
| | - A Mafrici
- San Carlo Borromeo Hospital, Milan, Italy
| | - E Riva
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - M G Franzosi
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - V Milani
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | | - G Mariani
- San Carlo Borromeo Hospital, Milan, Italy
| | - P M Piatti
- IRCCS-Ospedale San Raffaele, Milan, Italy
| | - M C Roncaglioni
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| |
Collapse
|
44
|
Sollini M, Boni R, Traino AC, Lazzeri E, Pasqualetti F, Modeo L, Mariani G, Petrini M, Erba PA. New approaches for imaging and therapy of solid cancer. Q J Nucl Med Mol Imaging 2015; 59:168-183. [PMID: 25693421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Radionuclide therapy is a systemic treatment that aims to deliver cytotoxic radiation to cancer cells. Due to their properties, antibodies have been considered as suitable agent for the delivery of therapeutic radioisotopes, radioimmunotherapy (RIT). This article gives an overview of new approaches for imaging and therapy of solid cancer with particular attention to strategies to enhance treatment success. Examples of increased antibody uptake by targeting stromal constituent of tumor microenvironment such as fibronectin (FN) an important tumor-associated angiogenesis targeting agent, with specifically designed antibody format will be provided. Strategies oriented to identify patients most likely to benefit from RIT including identification of radiosensitivity profiles, in vivo target identification by teragnostic approach and better prediction of dosimetric estimates would be presents. Combination regimens such as with chemo-radiotherapy and immunotherapy would be also discussed as an approach to enhance RIT success.
Collapse
Affiliation(s)
- M Sollini
- Nuclear Medicine Unit, Department of Oncology and Advanced Technology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy -
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Pietravalle P, Morano S, De Rossi MG, Mariani G, Cristina G, Ghirlanda G, Cotroneo P, Clementi A, Di Mario U. Protein charge permselectivity in type 2 and type 1 diabetes. Contrib Nephrol 2015; 101:135-8. [PMID: 8467666 DOI: 10.1159/000422121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- P Pietravalle
- Department of Endocrinology Clinica Medica 2, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Valdés Olmos RA, Rietbergen DD, Vidal-Sicart S, Manca G, Giammarile F, Mariani G. Contribution of SPECT/CT imaging to radioguided sentinel lymph node biopsy in breast cancer, melanoma, and other solid cancers: from "open and see" to "see and open". Q J Nucl Med Mol Imaging 2014; 58:127-139. [PMID: 24835289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A few years ago SPECT/CT was successfully incorporated into the sentinel node (SN) procedure for breast cancer and melanoma. Important contributions of SPECT/CT in these two malignancies were the anatomical localization of SNs already visualized on planar images, the detection of additional SNs in aberrant basins, and the depiction of SNs in cases with no visualization on planar images. Recently, in a large series of melanoma patients the use of SPECT/CT was associated with the detection of more metastatic SNs and a higher rate of disease-free survival. Following the experiences in breast cancer and melanoma, SPECT/CT has been applied in oral cavity cancer as well as in urological and gynaecological malignancies. In the areas of lymphatic drainage of these malignancies (head and neck, pelvis, and upper abdomen) SPECT/CT appears to be essential to localize SNs, providing surgeons with helpful anatomical landmarks to plan SN biopsies. In gastrointestinal and lung malignancies SPECT/CT has only incidentally been used. With the improvement of the CT component in the second generation of SPECT/CT gamma cameras, nuclear physicians today can identify lymph nodes corresponding with the radioactive SNs. This is possible using a display of SPECT/CT similar to that of conventional tomography. Multiplanar reconstruction enables to correlate radioactive sentinel nodes seen on fused SPECT/CT with lymph nodes seen on CT, and the use of cross-reference lines allows the navigation between axial, coronal and sagittal views. This visual information is helpful for the intraoperative procedure and for post-excision assessment using portable devices. Fused SPECT/CT images may also be three-dimensionally displayed, improving anatomical SN localisation and recognition. This recent imaging improvement is leading to a new paradigm of "see and open" in contraposition to the former "open and see" in the SN procedure. The new mixed reality protocols which are able to transfer SPECT/CT to the operating room for surgical navigation will reinforce this "see and open" concept. However, a comprehensive interpretation of SPECT/CT together with lymphoscintigraphy is necessary to identify radioactive lymph nodes as sentinel nodes and classify them into different categories that are important for the intraoperative procedure.
Collapse
Affiliation(s)
- R A Valdés Olmos
- Diagnostic Oncology, Nuclear Medicine Department Netherlands Cancer Institute Antoni van Leewenhoek Hospital Amsterdam, The Netherlands -
| | | | | | | | | | | |
Collapse
|
47
|
Manca G, Volterrani D, Mazzarri S, Duce V, Svirydenka A, Giuliano A, Mariani G. Sentinel lymph node mapping in breast cancer: a critical reappraisal of the internal mammary chain issue. Q J Nucl Med Mol Imaging 2014; 58:114-126. [PMID: 24835288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Although, like the axilla, the internal mammary nodes (IMNs) are a first-echelon nodal drainage site in breast cancer, the importance of their treatment has long been debated. Seminal randomized trials have failed to demonstrate a survival benefit from surgical IMN dissection, and several retrospective studies have shown that IMNs are rarely the first site of recurrence. However, the recent widespread adoption of sentinel lymph node (SLN) biopsy has stimulated a critical reappraisal of such early results. Furthermore, the higher proportion of screening-detected cancers, improved imaging and techniques (i.e., lymphoscintigraphy for radioguided SLN biopsy) make it possible to visualize lymphatic drainage to the IMNs. The virtually systematic application of adjuvant systemic and/or loco-regional radiotherapy encourages re-examination of the significance of IMN metastases. Moreover, randomized trials testing the value of postmastectomy irradiation and a meta-analysis of 78 randomized trials have provided high levels of evidence that local-regional tumor control is associated with long-term survival improvements. This benefit was limited to trials that used systemic chemotherapy, which was not routinely administered in the earlier studies. However, the contribution from IMN treatment is unclear. Lymphoscintigraphic studies have shown that a significant proportion of breast cancers have primary drainage to the IMNs, including approximately 30% of medial tumors and 15% of lateral tumors. In the few studies where IMN biopsy was performed, 20% of sentinel IMNs were metastatic. The risk of IMN involvement is higher in patients with medial tumors and positive axillary nodes. IMN metastasis has prognostic significance, as recognized by its inclusion in the American Joint Committee on Cancer staging criteria, and seems to have similar prognostic importance as axillary nodal involvement. Although routine IMN evaluation might be indicated, it has not been routinely performed, perhaps because IMN drainage with lymphoscintigraphy is more difficult to demonstrate than axillary drainage. This difference is due to technical reasons and not the absence of lymphatics to the IMN. Recent anatomical studies have confirmed a model of breast lymphatic drainage that comprises superficial, deep and perforating systems. The superficial system drains to the axilla, usually to a lymph node posterior to the pectoralis minor muscle. The deep system drains to the axilla and also anastomoses with the perforating system which drains to the IMNs. The perforating system does not connect with the superficial system. The prevalence of IMN drainage tends to reflect the method of lymphoscintigraphy, where peritumoral (deep lymphatic system) injections have a much higher likelihood of IMN drainage than subareolar or subdermal (superficial lymphatic system) injections. The fused SPECT/CT images represent a further technical solution to increase the identification of IMNs and consequently can significantly reduce the false negative rate of sentinel lymph node biopsy. Before mature results from current and future randomized trials assessing the benefit of IMN irradiation become available, lymphoscintigraphy and IMNs biopsy may be used to guide decisions regarding systemic and local-regional treatment. However, even in patients with visualized primary IMN drainage, the potential benefit of treatment should be balanced against the risk of added morbidity.
Collapse
Affiliation(s)
- G Manca
- Regional Center of Nuclear Medicine University of Pisa, Pisa, Italy -
| | | | | | | | | | | | | |
Collapse
|
48
|
Valdés Olmos RA, Vidal-Sicart S, Giammarile F, Zaknun JJ, Van Leeuwen FW, Mariani G. The GOSTT concept and hybrid mixed/virtual/augmented reality environment radioguided surgery. Q J Nucl Med Mol Imaging 2014; 58:207-215. [PMID: 24835294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The popularity gained by the sentinel lymph node (SLN) procedure in the last two decades did increase the interest of the surgical disciplines for other applications of radioguided surgery. An example is the gamma-probe guided localization of occult or difficult to locate neoplastic lesions. Such guidance can be achieved by intralesional delivery (ultrasound, stereotaxis or CT) of a radiolabelled agent that remains accumulated at the site of the injection. Another possibility rested on the use of systemic administration of a tumour-seeking radiopharmaceutical with favourable tumour accumulation and retention. On the other hand, new intraoperative imaging devices for radioguided surgery in complex anatomical areas became available. All this a few years ago led to the delineation of the concept Guided intraOperative Scintigraphic Tumour Targeting (GOSTT) to include the whole spectrum of basic and advanced nuclear medicine procedures required for providing a roadmap that would optimise surgery. The introduction of allied signatures using, e.g. hybrid tracers for simultaneous detection of the radioactive and fluorescent signals did amply the GOSTT concept. It was now possible to combine perioperative nuclear medicine imaging with the superior resolution of additional optical guidance in the operating room. This hybrid approach is currently in progress and probably will become an important model to follow in the coming years. A cornerstone in the GOSTT concept is constituted by diagnostic imaging technologies like SPECT/CT. SPECT/CT was introduced halfway the past decade and was immediately incorporated into the SLN procedure. Important reasons attributing to the success of SPECT/CT were its combination with lymphoscintigraphy, and the ability to display SLNs in an anatomical environment. This latter aspect has significantly been improved in the new generation of SPECT/CT cameras and provides the base for the novel mixed reality protocols of image-guided surgery. In these protocols the generated virtual SPECT/CT elements are visually superimposed in the body of the patient in the operating room to directly facilitate, by means of visualization on screen or using head-mounted devices, the localization of radioactive and/or fluorescent targets by minimal invasive approaches in areas of complex anatomy. All these technological advances will play an increasing role in the future extension and the clinical impact of the GOSTT concept.
Collapse
Affiliation(s)
- R A Valdés Olmos
- Diagnostic Oncology, Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leuwenhoek Hospital Amsterdam, The Netherlands -
| | | | | | | | | | | |
Collapse
|
49
|
Manca G, Romanini A, Rubello D, Mazzarri S, Boni G, Chiacchio S, Tredici M, Duce V, Tardelli E, Volterrani D, Mariani G. A critical reappraisal of false negative sentinel lymph node biopsy in melanoma. Q J Nucl Med Mol Imaging 2014; 58:105-113. [PMID: 24835287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Lymphatic mapping and sentinel lymph node biopsy (SLNB) have completely changed the clinical management of cutaneous melanoma. This procedure has been accepted worldwide as a recognized method for nodal staging. SLNB is able to accurately determine nodal basin status, providing the most useful prognostic information. However, SLNB is not a perfect diagnostic test. Several large-scale studies have reported a relatively high false-negative rate (5.6-21%), correctly defined as the proportion of false-negative results with respect to the total number of "actual" positive lymph nodes. The main purpose of this review is to address the technical issues that nuclear physicians, surgeons, and pathologists should carefully consider to improve the accuracy of SLNB by minimizing its false-negative rate. In particular, SPECT/CT imaging has demonstrated to be able to identify a greater number of sentinel lymph nodes (SLNs) than those found by planar lymphoscintigraphy. Furthermore, a unique definition in the international guidelines is missing for the operational identification of SLNs, which may be partly responsible for this relatively high false-negative rate of SLNB. Therefore, it is recommended for the scientific community to agree on the radioactive counting rate threshold so that the surgeon can be better radioguided to detect all the lymph nodes which are most likely to harbor metastases. Another possible source of error may be linked to the examination of the harvested SLNs by conventional histopathological methods. A more careful and extensive SLN analysis (e.g. molecular analysis by RT-PCR) is able to find more positive nodes, so that the false-negative rate is reduced. Older age at diagnosis, deeper lesions, histologic ulceration, head-neck anatomical location of primary lesions are the clinical factors associated with false-negative SLNBs in melanoma patients. There is still much controversy about the clinical significance of a false-negative SLNB on the prognosis of melanoma patients. Indeed, most studies have failed to show that there is worse melanoma-specific survival for false-negative compared to true-positive SLNB patients.
Collapse
Affiliation(s)
- G Manca
- Regional Center of Nuclear Medicine University of Pisa, Pisa, Italy -
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Morfini M, Batorova A, Mariani G, Auerswald G, Bernardi F, Di Minno G, Dolce A, Fede C, Giansily-Blaizot M, Ingerslev J, Martinowitz U, Napolitano M, Pinotti M, Schved JF. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost 2014; 112:424-5. [PMID: 24763923 DOI: 10.1160/th13-12-1045] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 03/11/2014] [Indexed: 12/17/2022]
Affiliation(s)
- M Morfini
- Massimo Morfini, Agency for Hemophilia and Regional Reference Center for Inherited Bleeding Disorders, Azienda Ospedalieriero, Universitaria Careggi, Florence, Italy, Tel.: +39 055 7947587, Fax: +39 055 7947794, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|